Typhoid vaccine - GlaxoSmithKline

Drug Profile

Typhoid vaccine - GlaxoSmithKline

Alternative Names: Typherix

Latest Information Update: 10 Dec 2001

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antibacterials; Bacterial vaccines; Polysaccharides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Typhoid

Most Recent Events

  • 10 Dec 2001 A study has been added to the Bacterial Infections immunogenicity section
  • 10 Dec 2001 Two studies have been added to the Bacterial Infections immunogenicity and adverse events sections ,
  • 23 Jan 2001 SmithKline Beecham has merged with Glaxo Wellcome to form GlaxoSmithKline
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top